IKNA - Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes | Benzinga
Thursday, Ikena Oncology Inc (NASDAQ:IKNA) announced an organizational streamlining to reallocate resources from exploratory research and discovery towards the ongoing targeted oncology clinical programs.
The company says it is laser-focused on IK-930 and IK-595:
IK-930: TEAD1-Selective Hippo Pathway Inhibitor
- The company has expanded and accelerated targeted recruitment of mesothelioma patients and additional epithelioid hemangioendothelioma patients.
- A clinical data update is planned for the second half of 2024.
IK-595: MEK-RAF Molecular Glue
- The initial cohort was dosed with IK-595 in December 2023 and subsequently cleared the safety evaluation window.
With the advancement of IK-930 and IK-595, the company has reduced its workforce by approximately 35%, which will be implemented over the first quarter of 2024.
With approximately $175 million in cash and cash equivalents as ...